Disease-modifying drugs for the early treatment of multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet359, 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Keegan BM, Noseworthy JH. Multiple sclerosis. Ann. Rev Med. 53, 285–302 (2002).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neumlogy46, 907–911 (1996).
   Google Scholar
• Weinshenker BG, Bass B, Rice GP et al The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain 112, 133–146 (1989).
   Google Scholar
• Galboiz J, Miller A. Immunological indicators of disease activity and prognosis in multiple sclerosis. CUI7: Opin. Neural 15, 233–237 (2002).
   Google Scholar
• Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends. Neumsci. 9, 271–277 (1986).
   Web of Science ®Google Scholar
• Brack W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatorycentral nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neural. 42,783–793 (1997).
   PubMed Web of Science ®Google Scholar
• Dalton CM, Brex PA, Jenkins R et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. j Neural Neurosurg. Byddatry73, 141–7 (2002).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mirk S, B6 L. Axonal transection in the lesions of multiple sclerosis. N Engl. I Med. 338, 278–285 (1998).
   Google Scholar
• Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Cun: Opin. Neural. 12,295-302 (1999).
   Google Scholar
• Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5,48–57 (1999).
   Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr et al Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Ailitylogy58, 169–178 (2002).
   Google Scholar
• •A review and consensus statement on the efficacy of disease-modifying therapies in multiple sclerosis (MS).
   Google Scholar
• Kurtzke JE Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33, 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Filippi M, Horsfield MA, Ader HJ et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann. Neural. 43, 499–506 (1998).
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Toyka KV, Austrian—German—Swiss Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis. Eur Neural. 42,121–127 (1999).
   Google Scholar
• •Consensus statement of the German-speaking Austrian—German—Swiss Multiple Sclerosis Therapy Consensus Group on the escalating imrnunotherapy of MS.
   Google Scholar
• The IFN-B Multiple Sclerosis Study Group. Interferon-0- lb is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43,655–661 (1993).
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al Intramuscular interferon-p-la for disease progression in relapsing multiple sclerosis. Ann. New& 39,285–294 (1996).
   Google Scholar
• PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon-p-la in relapsing/remitting multiple sclerosis. Lancet 352,1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl. Med. 317,408-414 (1987).
   Google Scholar
• Johnson IQ, Brooks BR, Cohen JA et al. Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. Neurology 45, 1268–1276 (1995).
   Google Scholar
• Johnson IQ, Brooks BR, Cohen JA et al Extended use of glatiramer acetate (Copaxone) is well-tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology50,701–708 (1998).
   Google Scholar
• Cord. G, Filippi M, Wolinsky JS, European/Canadian Glatiramer Acetate Study Group. European/Canadian, multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neural. 49,290–297 (2001).
   Google Scholar
• Johnson IQ, Brooks BR, Ford CC et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a 6-year organized multiple sclerosis trial. Mult. Scler. 9,585-591 (2003).
   Google Scholar
• MS-Therapie Konsensus Gruppe. Immunmodulatorische Stufentherapie der multiplen Sklerose. 1. Erganzung. Dezember 2000. Nervenatzt72, 150–157 (2001).
   Google Scholar
• •An update of reference [15] including the early use of disease-modifying treatments.
   Google Scholar
• Oger J, Freedman M. Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in multiple sclerosis. Can. New& Li 26,294 (1999).
   PubMed Web of Science ®Google Scholar
• •Consensus statement from Canada on the use of disease-modifying treatments in MS.
   Google Scholar
• Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361, 545–552 (2003).
   PubMed Web of Science ®Google Scholar
• Goodin S. Interferons in relapsing remitting multiple sclerosis. Lancet 361, 1821 (2003).
   PubMed Web of Science ®Google Scholar
• Kappos L, Kesselring J. Interferons in relapsing remitting multiple sclerosis. Lancet361, 1821–1822 (2003).
   PubMed Web of Science ®Google Scholar
• Paty D, Arnason B, Li D, Traboulsee A. Interferons in relapsing remitting multiple sclerosis. Lancet 361,1822 (2003).
   PubMed Web of Science ®Google Scholar
• Freedman M, King J, Oger J, Sharief M, Hartung HP, PRISMS Study Group. Interferons in relapsing remitting multiple sclerosis. Lancet 361,1822–1823 (2003).
   Google Scholar
• European Study Group on Interferon-3-lb in Secondary-Progressive MS. Placebo-controlled multicentre randomized trial of interferon-p-lb in treatment of secondary-progressive multiple sclerosis. Lancet 352, 1491–1497 (1998).
   Google Scholar
• Goodkin DE, North American Study Group on Interferon p-lb in Secondary-Progressive MS. Interferon-0 - lb in secondary-progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology54,2352 (2000)
   Google Scholar
• SPECTRIMS Study Group. Randomized controlled trial of interferon-3-la in secondary-progressive MS: clinical results. Neumlogy56, 1496–1504 (2001).
   PubMed Web of Science ®Google Scholar
• Li DK, Zhao GJ, Paty DW, UBC MS/MRI Analysis Research Group, SPECTRIMS Study Group. Randomized controlled trial of interferon-p-la in secondary-progressive MS: MRI results. Neurology56, 1505–1513 (2001).
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F, European Study Group on Interferon-3-lb in Secondary-Progressive MS. Final analysis of the European multicenter trial on IFN-0-lb in secondary-progressive MS. Neumlogy57, 1969-1975 (2001).
   Google Scholar
• Cohen JA, Cutter GR, Fischer JS et al. IMPACT Investigators. Benefit of interferon-3-la on MSFC progression in secondary-progressive MS. Neurology 59, 679–687 (2002).
   Google Scholar
• Hartung HP, Gonsette R, König N et al. Mitoxantrone in Multiple Sclerosis Study Group. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology61, 1332–1338 (2003).
   Google Scholar
• PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS 4. Long-term efficacy of interferon-3-la in relapsing MS. Neurology 56,1628–1636 (2001).
   Google Scholar
• Paty D, Kappos L, Stam Moraga M, Alsop J, Abdalla J, PRIMS Group. Long-term observational efficacy and safety follow-up of the PRISMS cohort. 19th Congress of the European Committee for Research and Treatment in MS, Milan, 17–20 September (2003).
   Google Scholar
• Jacobs LD, Beck R, Simon JH et al. Intramuscular interferon-p- la therapy initiated during a first demyelinating event in multiple sclerosis. N Engl. I Med. 343, 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial in patients with clinically isolated syndroms suggestive of MS (Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevetion Study).
   Google Scholar
• Comi G, Filippi M, Barkhof F et al Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357, 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• ••Phase III clinical trial in patients withclinically isolated syndroms suggestive of MS (Early Treatment of Multiple Sclerosis Study).
   Google Scholar
• Jeffery DR. Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. j Neural. Sc]. 197, 1–8 (2002).
   PubMed Web of Science ®Google Scholar
• Coyle PK, Hartung HP Use of interferon-0 in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult. Scler. 8, 2–9 (2002).
   Google Scholar
• Bay-as A, Rieckmann P Managing the adverse effects of interferon-0 therapy in multiple sclerosis. Drug. Sal 22,149–159 (2000).
   Google Scholar
• Ziemssen T, Neuhaus O, Hohlfeld R. Risk—benefit assessment of glatiramer acetate in multiple sclerosis. Drug. Sal 24, 979–990 (2001).
   Google Scholar
• Durelli L, Verdun E, Barbero P et al. Every- other-day interferon-0-1b versus once-weekly interferon-0-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 359,1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G et al EVIDENCE Study Group, University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon-0-1a treatment regimens in MS: the EVIDENCE Trial. Neurology59, 1496–1506 (2002).
   Google Scholar
• Clanet M, Radue EW, Kappos L et al European IFN-0-1a (Avonex) Dose-Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon-0-1a in relapsing MS. Neurology59, 1507–1517 (2002).
   Google Scholar
• Maurer M, Rieckmann P Relapsing- remitting multiple sclerosis. What is the potential for combination therapy? Biodrugs 13,149–158 (2000).
   Google Scholar
• •Review on the rationale and potential of combination therapies in MS.
   Google Scholar
• Noseworthy JH. Management of multiple sclerosis: current trials and future options. Gun: Opin. Neural. 16, 289–297 (2003).
   Google Scholar
• •Overview of currently performed and/or planned clinical trials.
   Google Scholar
• National Multiple Sclerosis Society USA (NMSS). Disease management consensus statement wwwnnmorg (Accessed April 2004)
   Google Scholar